FDA clears Abbott’s Alinity h-series hematology system

Abbott has received U.S. Food and Drug Administration clearance for its advanced Alinity h-series hematology system, paving the way for laboratories throughout the country to run complete blood counts as a part of Abbott’s Alinity family of diagnostic products. The Alinity h-series includes Alinity hq, an automated hematology analyzer, and Alinity hs, an integrated slide maker and stainer. A key differentiator for Alinity hq is that it leverages the advanced MAPSSTM technology, which uses light scattering to distinguish cellular features and better identify various blood cells. The Alinity family of systems in the U.S. now includes the Alinity h-series — hematology, Alinity ci — clinical chemistry and immunoassay, Alinity m — molecular, Alinity s — transfusion, and the point-of-care i-STAT Alinity. The Alinity h-series system offers several advantages for laboratories: Processes up to 119 CBC results per hour, among the fastest on the market; Requires less floor space, which is critical for labs to maximize resources and operations; Loads samples from the front and from a laboratory automation system; Ensures urgent samples receive priority without compromising capacity or workflow; Offers hands-off maintenance so labs can schedule automated daily and weekly cleanings; Integrates the slide maker with the analyzer to reduce manual intervention; Provides customizable reports and rules for systems; and Centralizes results and control functions at a single point.